

Yasuo Hamamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5141928/publications.pdf>

Version: 2024-02-01

62
papers

4,013
citations

471509

17
h-index

138484

58
g-index

64
all docs

64
docs citations

64
times ranked

4567
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471.	13.7	1,749
2	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1506-1517.	10.7	767
3	Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 631-639.	10.7	324
4	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	5.3	155
5	An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. <i>Cell</i> , 2020, 183, 1420-1435.e21.	28.9	111
6	Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. <i>British Journal of Cancer</i> , 2016, 115, 1328-1334.	6.4	108
7	A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1265-1272.	2.3	102
8	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	5.3	61
9	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). <i>Gastric Cancer</i> , 2019, 22, 344-354.	5.3	60
10	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	5.3	45
11	<p>Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4585-4593.	1.9	37
12	Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3). <i>Esophagus</i> , 2021, 18, 90-99.	1.9	30
13	Three-Year Follow-Up and Response"Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). <i>Clinical Cancer Research</i> , 2022, 28, 3277-3286.	7.0	27
14	Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. <i>Gastric Cancer</i> , 2018, 21, 429-438.	5.3	26
15	Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2129-2134.	2.3	24
16	Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors. <i>Scientific Reports</i> , 2021, 11, 20003.	3.3	23
17	Long&term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. <i>Cancer Science</i> , 2020, 111, 1676-1684.	3.9	21
18	Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS175-TPS175.	1.6	19

#	ARTICLE	IF	CITATIONS
19	Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy. <i>Molecular and Clinical Oncology</i> , 2015, 3, 539-542.	1.0	17
20	Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report. <i>Oncology Letters</i> , 2016, 11, 231-233.	1.8	17
21	Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: A qualitative study. <i>European Journal of Oncology Nursing</i> , 2019, 38, 65-69.	2.1	17
22	A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposureâ€“Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). <i>Clinical Colorectal Cancer</i> , 2020, 19, 13-21.e3.	2.3	17
23	A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study). <i>Oncologist</i> , 2014, 19, 1131-1132.	3.7	15
24	Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07). <i>Esophagus</i> , 2021, 18, 835-843.	1.9	15
25	Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. <i>Future Oncology</i> , 2021, 17, 2593-2603.	2.4	14
26	FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E)â€“The short-term results of cohort A and B.. <i>Journal of Clinical Oncology</i> , 2021, 39, 202-202.	1.6	13
27	Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 595-602.	2.3	12
28	Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 60-67.	2.2	12
29	A phase II study of chemoselection with docetaxel, cisplatin, and 5â€“fluorouracil as a strategy for organ preservation in patients with resectable esophageal cancer (CROC trial).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4027-4027.	1.6	12
30	Multicenter questionnaire survey on patterns of care for elderly patients with esophageal squamous cell carcinoma by the Japan Esophageal Oncology Group. <i>Japanese Journal of Clinical Oncology</i> , 2015, 46, hv183.	1.3	11
31	Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. <i>Gastric Cancer</i> , 2016, 19, 876-886.	5.3	10
32	Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma. <i>Esophagus</i> , 2017, 14, 324-332.	1.9	9
33	Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. <i>Future Oncology</i> , 2018, 14, 3187-3198.	2.4	9
34	Pilot study of WT1 peptideâ€“pulsed dendritic cell vaccination with docetaxel in esophageal cancer. <i>Oncology Letters</i> , 2018, 16, 1348-1356.	1.8	9
35	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	5.3	9
36	Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case report. <i>Oncology Letters</i> , 2016, 11, 2408-2410.	1.8	8

#	ARTICLE	IF	CITATIONS
37	Treatment selection for esophageal cancer: evaluation from a nationwide database. <i>Esophagus</i> , 2018, 15, 109-114.	1.9	8
38	Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2018, 5, 172-177.	1.6	8
39	Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 204-204.	1.6	8
40	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. <i>JCO Precision Oncology</i> , 2022, 6, e2100383.	3.0	8
41	Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study). <i>Oncology Letters</i> , 2016, 11, 4049-4054.	1.8	7
42	Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group. <i>BMC Cancer</i> , 2020, 20, 548.	2.6	7
43	Achieving sequential therapy in advanced gastric cancer: the importance of appropriate patient management for the elderly and/or those with ascites. <i>Gastric Cancer</i> , 2020, 23, 363-372.	5.3	7
44	Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis. <i>Investigational New Drugs</i> , 2018, 36, 939-948.	2.6	5
45	Small intestinal perforation due to a huge gastrointestinal stromal tumor in a kidney transplant recipient: a case report and literature review. <i>BMC Nephrology</i> , 2019, 20, 120.	1.8	5
46	Prospective evaluation and refinement of an Sa _{cr} dosage formula based on renal function for clinical application. <i>Cancer Science</i> , 2021, 112, 751-759.	3.9	5
47	Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 389-392.	1.3	4
48	Falls and Physical Inactivity in Patients with Gastrointestinal Cancer and Hand–Foot Syndrome. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2018, 5, 307.	1.6	4
49	Management of elderly patients with esophageal squamous cell cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 816-824.	1.3	4
50	Case series of preoperative triplet-regimen (docetaxel, CDDP and 5-fluorouracil) for borderline resectable T4 thoracic esophageal carcinoma. <i>Esophagus</i> , 2013, 10, 205-210.	1.9	3
51	Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 27.	1.9	3
52	The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study. <i>Diagnostics</i> , 2021, 11, 543.	2.6	3
53	A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 199-204.	1.3	2
54	WJOG13219G: Triplet versus doublet in patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer: A multi-institutional real-world data analysis (BRACELET study).. <i>Journal of Clinical Oncology</i> , 2022, 40, 37-37.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Curative resectability of gastrointestinal cancer identified from iron deficiency anemia. <i>Oncology Letters</i> , 2017, 14, 4301-4304.	1.8	1
56	Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report. <i>Oncology Letters</i> , 2017, 14, 3697-3700.	1.8	1
57	Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 120-120.	1.6	1
58	A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT).. <i>Journal of Clinical Oncology</i> , 2022, 40, 280-280.	1.6	1
59	Need for prospective collection of experience and repeated samples in esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2018, 10, S2086-S2088.	1.4	0
60	Early administration of systemic chemotherapy should be considered for scirrhous gastric cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 10, 113-117.	1.0	0
61	Meta-analysis of postprogression survival for first-line gemcitabine monotherapy in patients with advanced pancreatic cancer: Positive relationship between subsequent anti-cancer therapy and overall survival.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15687-e15687.	1.6	0
62	Phase II study of chemoselection with docetaxel plus 5-fluorouracil and cisplatin induction chemotherapy and subsequent conversion surgery for locally advanced unresectable esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4021-4021.	1.6	0